

NORTH CENTRAL CANCER TREATMENT GROUP

N08C7 Continuation Phase Eligibility Checklist

10/09/2009

Page 1 of 1

N08C7: Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Flaxseed for the Treatment of Hot Flashes

If the patient and physician/allied health staff want to continue with the active agent, or if on placebo, begin the active agent, fax (507/284-0885) a completed continuation phase eligibility checklist to the Registration Office between 8 a.m. and 4:30 p.m. central time Monday through Friday.

Registration date (date on) (mm/dd/yyyy) __ __/__ __/____
Patient study ID number (provided at time of Reg/Random) _____
NCCTG member (participant sponsor) _____
NCCTG treating location _____
NCCTG treating physician/allied health care provider _____
Institution patient number (local subject number) _____
IRB approval date (mm/dd/yyyy) __ __/__ __/____
<u>Person Completing Form:</u>
Last Name: (print) _____ First Name: (print) _____
Phone: _____ Fax: _____ Email: _____

Eligibility Check - Answer questions below (yes/no). All requirements must be confirmed. All dates are to be mm/dd/yyyy.

Registration Check

Yes No

The double-blind phase of the study must be completed prior to the treatment code being broken; that is, after the treating site has received the completed patient questionnaire booklet.	____	____
Treatment cannot begin prior to registration and must begin \leq 28 days after registration to the continuation phase.	____	____

All responses in above section must be "Yes"

Assigned Treatment

_____ Flaxseed

Person registering Signature _____ Registration Office specialist initials _____

Physician/Allied Health Care Provider Signature _____ Date (mm/dd/yyyy) __ __/__ __/____